Results 181 to 190 of about 615,594 (260)

Drivers and barriers to influenza vaccination in the post-COVID-19 era in the Federation of Bosnia and Herzegovina: A qualitative study using focus groups with risk groups and in-depth interviews with physicians. [PDF]

Hum Vaccin Immunother
Musa S, Bosankic Cmajcanin N, Skocibusic S, Draganovic S, Bresee J.   +4 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Prolactin gene diversity and its influence on milk yield traits in Ayrshiredairy cattle from Southern Russia. [PDF]

J Adv Vet Anim Res
Shirokova NV, Fiodorov VK, Gorlov IF, Slozhenkina MI, Anisimova EY, Mosolova NI.   +5 more
europepmc   +1 more source

Antidepressants and the risk of hyponatremia: A multi‐institutional cohort study using observational medical outcomes partnership—Common Data Model

British Journal of Clinical Pharmacology, EarlyView.
Aim Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023 ...
Kyungyeon Jung, Ju Hwan Kim, Da Eun Hyeon, Jeongmoon Ji, Min Young Lee, Hayun Choi, Dong Yun Lee, Min Woo Kim, Yoonmin Jang, Seonghoon Hwang, Jaehyeong Cho, Seok Young Song, Sang Youl Rhee, Jae Myung Cha, Won‐Woo Seo, Chang‐Won Jeong, Seung‐Jin Kwag, Woo Jin Kim, Jaeuk Hwang, Min‐ho Kim, Rae Woong Park, Ju‐Young Shin   +21 more
wiley   +1 more source

Long-term outcomes of the use of a polytetrafluoroethylene-valved conduit for right ventricular outflow tract reconstruction in adult Ross patients. [PDF]

J Cardiothorac Surg
Kashapov R, Afanasyev A, Sharifulin R, Astapov D, Demin I, Rosseykin E, Bogachev-Prokophiev A.   +6 more
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Revealing Majorana Zero Modes in Vortex Cores via Nonmagnetic Impurities. [PDF]

Research (Wash D C)
Neverov VD, Karabassov T, Krasavin AV, Roditchev D, Stolyarov VS, Vagov A.   +5 more
europepmc   +1 more source

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway, Cinzia Dello Russo, Nicholas Bass, Elvira Bramon, Helen Cross, Natalie Curley, Sarah Curran, Helen Davies, Jana De Villiers, William Evans, Bernhard Frank, Alice Groves, Judith Hayward, Jon Higham, Dyfrig A. Hughes, Shwe Sin Kyaw, Anthony G. Marson, Ailsa McLellan, Seth Mensah, Francis O'Neill, Jane Sargison, Sanjay M. Sisodiya, Jill Swan, Joanna M. Zakrewska, Munir Pirmohamed   +24 more
wiley   +1 more source